NEWM&A

Biogen (BIIB) to Acquire Apellis for $5.6 Billion

Published on 4/1/2026

#BIIB#M&A#Pharmaceuticals#Acquisition
Biogen (BIIB) to Acquire Apellis for $5.6 Billion

AI Summary

Biogen (BIIB) announced plans to acquire Apellis Pharmaceuticals for $5.6 billion. This acquisition aims to enhance Biogen's portfolio in the neurological disorders market. The transaction is expected to be finalized in the second half of 2024, pending regulatory approvals. This move may increase Biogen's market presence and influence, reflecting its strategy to diversify and grow its offerings post patent expirations of major products.

Source: Read original article (opens in new tab)

Related News

Raiders (LV) Sale Approved at $11 Billion Valuation for 3.5% Stake
M&A

Raiders (LV) Sale Approved at $11 Billion Valuation for 3.5% Stake

Apr 1

Fidelity (FDBC) to acquire Affinity Bancshares for $142.8 million
M&A

Fidelity (FDBC) to acquire Affinity Bancshares for $142.8 million

Apr 1

Home Depot (HD) Expands $100B Market with Mingledorff’s Acquisition
M&A

Home Depot (HD) Expands $100B Market with Mingledorff’s Acquisition

Apr 1

Citigroup Lowers Price Target on SL Green Realty (SLG) to $45
M&A

Citigroup Lowers Price Target on SL Green Realty (SLG) to $45

Apr 1